Welcome to our dedicated page for Cosmos Holdings news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Holdings stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (COSM) announced that subsidiary Cana Laboratories has signed new five-year contract manufacturing agreements with Target Pharma covering approximately 5.2 million units, or about 1.04 million units annually.
The agreements for MUPIROCIN and TRETIN lift Cana’s cumulative orderbook to more than 32.7 million units, a 31% increase since June 2026, achieved through two agreements signed in under two weeks. September contracted volume additions total 7.7 million units, including the previously announced five-year ROSARTIA agreement with Viofar.
Cana’s contracted portfolio now spans 11 therapeutic categories, up from nine in June, with new coverage in cardiovascular and anti-infective. Agreements across the division extend up to ten years, which the company expects will support recurring production and associated cash flows.
Cana operates a 54,000-square-foot GMP-licensed, EMA-certified facility in Athens, upgraded with about $5.5 million of investment, and is targeted, at full capacity, to generate over $10 million in recurring annual profit.
Cosmos Health (COSM) has engaged Prime Ledger to structure a proposed tokenized, asset-specific, non-dilutive financing backed by the intellectual property of CCX0722, an ingestible hydrogel-based medical device in development for weight management.
The structure is designed to fund CCX0722 without issuing Cosmos Health common stock, while the company expects to retain future economic benefits from the asset. CCX0722 uses a superabsorbent hydrogel that expands more than 100-fold in the stomach, has no systemic absorption, and passes naturally through the gastrointestinal tract. Cosmos Health consolidated full ownership of the core patent application WO2025108566A1 in June 2026, which has entered regional or national phases in the United States, Europe, Australia and Canada. The program targets a weight-management market projected at $562.2 billion by 2033 and sits within a broader tokenized real‑world‑asset market projected at $18.9 trillion by 2033. Initial structuring work is targeted for completion in Q4 2026, and there is no assurance any offering will be completed.
Cosmos Health (COSM) announced a new five-year contract manufacturing agreement for approximately 2.5 million units of ROSARTIA with Viofar. The deal, equal to about 500,000 units annually across four dosage strengths, lifts subsidiary Cana Laboratories’ cumulative contract manufacturing orderbook to more than 27.5 million units, up from over 25 million in June 2026. The agreement expands Cana’s presence in cardiovascular pharmaceuticals, enhances visibility into future production volumes and recurring cash flows, and further utilizes its EMA-certified, GMP-licensed manufacturing facility in Athens, Greece.
Cosmos Health (COSM) has launched its new veterinary antimicrobial cleanser C-ScrubVet Wash 4% CHDG in the United Kingdom, marking its commercial entry into the approximately $69 billion global animal health market.
The product contains 4% chlorhexidine digluconate and is certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use. It is formulated for dogs, cats, horses, companion and large animals and supplied as a 500ml biocide for external use in a pump-dispenser bottle. Initial sales are e-commerce led in the UK, with additional European markets targeted from Q4 2026 and planned expansion into pet store chains and veterinary clinics.
C-ScrubVet is manufactured in-house at Cana Laboratories’ EU GMP-licensed, EMA-certified facility and extends the established C-Scrub brand beyond human healthcare. The company highlights this launch as a new growth channel alongside its core pharmaceutical and nutraceutical business, which generated record fiscal 2025 revenue of $65.27 million, up 20% year-over-year, and as one of several catalysts expected to support previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31.0 million in net income.
Cosmos Health (COSM) reported three consecutive record revenue periods through H1 2026, while deleveraging its balance sheet and streamlining its capital structure.
Revenue rose to $65.27M in FY2025 (+20% YoY), then to $17.93M in Q1 2026 (+30.7%) and $18.99M in Q2 2026 (+28.8%), for H1 2026 revenue of $36.91M (+29.7%). Adjusted gross profit grew 83% in 2025 to $7.9M, and H1 2026 adjusted gross profit increased 58% YoY. Total liabilities fell to $40.79M, down 13.3% from year-end 2025, while stockholders’ equity rose 12.2% to $20.67M.
The company fully repaid an $8.0M ATW convertible note 12 months early, withdrew shelf registrations, allowed 4.87M Series B warrants to expire, and repurchased 5.1M+ shares for about $1.11M under a $5M authorization. Management highlighted non-core assets of about $20M, a growing digital asset and real estate portfolio, new IP such as the CCX0722 hydrogel patent filings, UK retail wins for C‑Scrub, Gulf-region distribution deals for Sky Premium Life, and reaffirmed 2026 revenue guidance of $90M+ and 2029 targets of $200.6M revenue and $31.0M net income.
Cosmos Health (NASDAQ:COSM) retired its $8.0 million senior secured ATW convertible note, including accrued interest, twelve months before its August 2027 maturity, eliminating further dilution from conversions and reducing interest expense. The note, issued in August 2025 with a 9% coupon, significantly deleverages the balance sheet.
According to Cosmos Health, second-quarter results showed total liabilities down $6.27 million (13.3%), stockholders' equity up 12.2%, and the liabilities‑to‑assets ratio improving by 550 bps. The company has withdrawn its Form S‑1 and Form S‑3 registration statements and currently has no effective shelf or ATM program, no structured warrants and no variable‑rate instruments without a floor. Operating cash requirements in first‑half 2026 ran 30%+ below the average of the prior two years, and a $5.0 million share repurchase program is underway, supported by a diversified asset base that includes Bitcoin holdings currently in a gain position.
Cosmos Health (NASDAQ:COSM) projects its whole-olive polyphenol nutraceutical Oliv18™ to generate over $6 million in incremental annual U.S. revenue within 12–18 months, with about $4.3 million gross profit at an estimated 72% gross margin, according to Cosmos Health.
Oliv18™, part of the company’s “18 Series,” targets the U.S. cardiovascular health and antioxidant supplement categories via a staged rollout, starting with direct-to-consumer e-commerce and later selected retail channels. Cosmos Health notes its forecast is based on internal assumptions and successful execution of commercialization plans.
Cosmos Health (NASDAQ:COSM) has signed an exclusive distribution agreement with Innova Healthcare, one of Saudi Arabia’s largest retail pharmacy networks, for its Sky Premium Life food supplements across the Kingdom of Saudi Arabia. The deal includes an initial purchase order of 126,000 units.
Innova is appointed sole distributor for registration, distribution, promotion, marketing, logistics and sales across pharmacies, retail shops and online platforms, for an initial five-year term with an option to renew for another five years. Innova also receives a first right of refusal on new Cosmos Health products during the term. Cosmos Health expects to receive orders of more than 5 million units over the initial five-year period, based on current assumptions. The agreement provides access to Innova’s network of 250+ pharmacies in 12 Saudi cities and villages and entry into a Saudi nutraceuticals market estimated at $3.26 billion in 2024 and forecast to reach $5.96 billion by 2033.
Cosmos Health (NASDAQ:COSM) reported record Q2 2026 revenue of $18.99 million, up 28.8% year over year, and first‑half revenue of $36.91 million, up 29.7%. Adjusted revenue reached $19.32 million in Q2 and $37.72 million in H1. Adjusted gross profit rose 58.4% to $1.84 million in Q2, with adjusted gross margin expanding 165 bps to 9.54%, while operating expenses increased 16.5%, below the revenue growth rate.
Net loss widened to $6.09 million in Q2 and $8.89 million in H1, largely due to $2.65 million of non‑cash fair‑value charges. Adjusted EBITDA improved slightly to a loss of $1.13 million in Q2. Total liabilities fell 13.3% to $40.79 million, stockholders' equity increased 12.2% to $20.67 million, and liquid assets stood at $4.15 million. Under a $5.0 million share repurchase program running through December 31, 2026, Cosmos has bought back about 5.1 million shares for $1.11 million to date.
Cosmos Health (NASDAQ:COSM) announced the active development of a flexible, technology-driven digital subscription platform to unify its proprietary consumer health products across both B2C and B2B channels. Customers will be able to start via a free nutritionist consultation, an AI-powered assistant, or by building their own package.
The platform is being designed to support consumer subscriptions at chosen frequencies, corporate subscriptions for employee wellness and gifting with multi-recipient tools, tiered pricing, centralized billing, and one-time or gift purchases. According to Cosmos Health, the initiative builds on its U.S. NOOR Collagen subscription model, which has achieved an early repeat purchase rate above 60%, and is intended to scale into international markets and support a recurring-revenue business model.